ArticleCancers2021
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.NPJ precision oncology · 2026Article
- The state of the art in artificial intelligence and digital pathology in prostate cancer.Nature reviews. Urology · 2026Review
- Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.BMC cancer · 2025Article
- DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.British journal of cancer · 2024Article
- Article
- Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Biomarkers in the Era of Precision Oncology.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Machine learning (ML) is expected to improve biomarker assessment. Using convolution neural networks, we developed a fully-automated method for assessing PTEN protein status in immunohistochemically-stained slides using a radical prostatectomy (RP) cohort (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.